 PALO ALTO, Calif., March 9, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus HDV infection, today reported financial results for fourth quarter and full year 2020 and provided a business update. 